



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-190001	Application No. 10/789,247
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date February 27, 2004	Group Art Unit 1616

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
MS	A1	5,552,143	Sept. 3, 1996	Plotkin et al.			
MS	A2	5,591,439	Jan. 7, 1997	Plotkin et al.			
MS	A3	5,720,957	Feb. 24, 1998	Jones et al.			
MS	A4	5,728,578	Mar. 17, 1998	Jahn et al.			
MS	A5	5,800,981	Sept. 1, 1998	Bruggeman et al.			
MS	A6	5,846,733	Dec. 8, 1998	Jahn et al.			
MS	A7	6,448,389	Sep. 10, 2002	Gonczol et al.			
	A8						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
MS	B1	EP 0 389 286 B1	26/09/1990	Europe				
MS	B2	EP 0 252 531 B	02/12/1992	Europe			X (abstract)	
MS	B3	WO 97/40165	30/10/1997	WIPO				
MS	B4	EP 0 236 145	09/09/1987	Europe				
MS	B5	WO 01/72782	04/10/2001	WIPO				
MS	B6	WO 02/34769	02/05/2002	WIPO				
	B7							

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MS	C1	Adler et al., "A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)," J. Infect. Dis. 180(3):843-6 (1999)
MS	C2	Berencsi et al., "A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects," J. Infect. Dis. 183(8):1171-9 (2001)
MS	C3	Britt and Alford, "Cytomegalovirus," Fields Virology, 3d Ed., Chapter 77:2493-2523 (1996)
MS	C4	Cull et al., "Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice," Gene Ther. 9(20):1369-78 (2002)

Examiner Signature /Magdalene Sgagias/	Date Considered 12/19/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07917-190001	Application No. 10/789,247
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date February 27, 2004	Group Art Unit 1616

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
MS	C5	Endresz et al., "Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization," Vaccine 17:50-58 (1999)
MS	C6	Endresz et al., "Optimization of DNA immunization against human cytomegalovirus," Vaccine 19:3972-80 (2001)
MS	C7	La Rosa et al., "Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice," Blood 100(10):3681-3689 (2002)
MS	C8	Lu et al., "Antigen Engineering in DNA Immunization," Methods in Molecular Medicine 29:355-74 (2000)
MS	C9	Mach et al., "Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73)," J. Virol. 74(24):11881-92 (2000)
MS	C10	Morello et al., "Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication," J. Virol. 76(10):4822-35 (2002)
MS	C11	Temperton, "DNA vaccines against cytomegalovirus: current progress," Intl. J. Antimicrobial Agents 19:169-72 (2002)
MS	C12	Oh et al., "Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery," Vaccine 19(31):4519-25 (2001)
MS	C13	S.A. Plotkin, "Vaccination against cytomegalovirus," Arch. Virol. 17:121-34 (2001)
MS	C14	Scholl et al., "Prokaryotic expression of immunogenic polypeptides of the large phosphoprotein (pp150) of human cytomegalovirus," J. Gen. Virol. 69 (Pt 6):1195-204 (1988)
MS	C15	Spaete et al., "Coexpression of Truncated Human Cytomegalovirus gH with the UL115 Gene Product or the Truncated Human Fibroblast Growth Factor Receptor Results in Transport of gH to the Cell Surface," Virology 193(2):853-61 (1993)
MS	C16	Walker et al., "Characterization of Human Cytomegalovirus Strains by Analysis of Short Tandem Repeat Polymorphisms," J. Clin. Microbio. 39:2219-26 (2001)
	C17	

Examiner Signature /Magdalene Sgagias/	Date Considered 12/19/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	